Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer Read more about Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans Read more about Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans
Amgen To Webcast 2014 Business Review Meeting On October 28 Read more about Amgen To Webcast 2014 Business Review Meeting On October 28
Amgen Announces Webcast of 2014 Third Quarter Financial Results Read more about Amgen Announces Webcast of 2014 Third Quarter Financial Results
Amgen Statement Regarding Third Point Investment Read more about Amgen Statement Regarding Third Point Investment
Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors Read more about Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors
Amgen Announces 2014 Fourth Quarter Dividend Read more about Amgen Announces 2014 Fourth Quarter Dividend
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement Read more about Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia Read more about Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis Read more about Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis
